Description
Ivrea (Ivermectin) 1% Cream
Ivrea 1% cream contains ivermectin, a topical antiparasitic medicine used for inflammatory lesions of papulopustular rosacea. Regulatory prescribing information for ivermectin 1% cream identifies it as a topical medicine for rosacea rather than a general treatment for unspecified skin parasites.
Active Ingredient and Medicine Class
The active ingredient is ivermectin, a member of the avermectin family of macrocyclic lactones. It is classified as a topical antiparasitic agent with anti-inflammatory activity discussed in the medical literature.
Established Medical Uses
Verified prescribing information and clinical studies support use of ivermectin 1% cream for inflammatory lesions of rosacea, especially papulopustular rosacea in adults. Clinical trials showed improvement in lesion counts and global severity scores compared with vehicle, and review articles describe its established role in rosacea management.
How It Works
The exact mechanism for rosacea is not fully established in prescribing information. Published reviews indicate that topical ivermectin may help through a combination of anti-inflammatory effects and activity against Demodex mites, which are thought to contribute to papulopustular rosacea in some patients.
Important Safety Information
Ivermectin 1% cream should not be used in people with known hypersensitivity to ivermectin or any component of the formulation. FDA prescribing information states that safety and effectiveness in pediatric patients have not been established. The label also notes caution in nursing mothers because the potential risk to infants is uncertain. Clinically important medication interactions are not prominently identified in the topical label, but product-specific prescribing information should always be reviewed.
Possible Side Effects
Commonly reported adverse effects include skin burning sensation, pruritus, dry skin, and skin irritation. Clinical studies and reviews also describe generally good local tolerability. Serious reactions are uncommon, but any unexpected severe skin reaction should be treated as medically important.
Scientific Evidence
Two pivotal randomized, double-blind studies found that once-daily ivermectin 1% cream was superior to vehicle for reducing inflammatory lesions and achieving treatment success in moderate to severe papulopustular rosacea. Review literature and meta-analyses also support its efficacy, safety, and tolerability as a topical option for rosacea.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, product label, or assessment by a qualified healthcare professional.
Medical Sources
- FDA: SOOLANTRA (ivermectin) cream, 1% prescribing information
- Linda Stein et al.: “Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies,” J Drugs Dermatol, 2014. PubMed
